Enhancement of taxane-based chemotherapy by a CDK1 antagonist
AssigneeYale University
InventorsDario C. Altieri, Daniel S. O'Connor
Life of this patent
Estimating the term…
Abstract
The present invention provides a combination therapy for inhibiting the growth of tumor, for treating cancer, and for inducing cell death. The therapy comprises the sequential administration of taxane and a CDK1 antagonist. The present invention also provides pharmaceutical compositions comprising taxane and a CDK1 antagonist and kits comprising taxane and CDK1 antagonist.
Claims45
A method of inducing tumor cell apoptosis comprising administering at least one compound that arrests cell mitosis and at least one compound that inhibits a survivin function.
A method of inhibiting tumor growth comprising administering at least one compound that arrests cell mitosis and at least one compound that inhibits a survivin function.
A method of inducing cell death in a malignant cell population comprising administering at least one compound that arrests cell mitosis and at least one compound that inhibits a survivin function.
A method of treating a patient with cancer comprising administering at least one compound that arrests cell mitosis and at least one compound that inhibits a survivin function.
A sequential therapy comprising administering a compound that arrests cell mitosis and a compound that inhibits a survivin function.
A pharmaceutical composition comprising a compound that arrests cell mitosis and a compound that inhibits a survivin function.
A pharmaceutical composition comprising an effective dose of a compound that arrests cell mitosis and a compound that inhibits survivin function.
A kit comprising a compound that arrests cell mitosis and a compound that inhibits a survivin function.
A kit comprising an effective dose of a compound to arrest cell mitosis and an effective dose of a compound to inhibit a survivin function.
Dependencies are inferred from the claim text.